The United States Food and Drug Administration reported a recall by BRS Analytical Services on five eye care products ...

Spring has been bountiful at Cleveland's Abeona Therapeutics. | As Abeona gears up for the commercial rollout of Zevaskyn, ...

Medicus to acquire Antev and expand into urology with Teverelix while reporting positive data in its Phase 2 skin cancer ...

It's a healthy, go-to breakfast item, but 12 flavors from one brand were just given the highest possible risk level by the ...

Five AvKARE products sold nationwide were affected.The FDA warns that there is a low risk of temporary health effects if the ...

Several eye care products have been recalled nationwide due to potential safety risks. BRS Analytical Service, LLC initiated the voluntary recall after manufacturing issues raised possible concerns ...

Full data from Group 1 of the Phase 2 REGEN-007 study are expected in Q2 2025 and will comprise approximately 20 patients who have received two rilparencel injections, with an average follow-up of ...

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or "ZyVersa”), a clinical-stage specialty biopharmaceutical company developing ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 second quarter ended March 31, 2025. The Company is hosting a conference call today, May 12, 2025, ...

A nationwide recall has been issued for a number of eye care products in the U.S. as officials urged people to stop using them "immediately." ...

Leading cancer researchers from UC San Francisco presented talks about advances in targeted therapies, cancer genomics, using AI to personalize cancer treatment, improving diagnosis of hard-to-treat ...